Stemness markers and used functional stem-cell assays
Murine markers . | Normal vs disease . | Human markers . | Patient-derived xenograft . | Single-cell RNA sequencing . | References . |
---|---|---|---|---|---|
Lin−/LSK | 41-46 | ||||
Lin−/LSK | + | 47 | |||
LSK-SLAM | 38,48-56 | ||||
LSK-SLAM | + | 57-59 | |||
LSK-SLAM | + | 60-63 | |||
LSK-SLAM | + | + | 64-67 | ||
LSK-SLAM | CD34+/CD38+CD38− | 34,57,68-73 | |||
LSK-SLAM | + | 74,75 | |||
CD34+/CD38+CD38− | 33,76-78 | ||||
CD34+/CD38+CD38− | + | 37,39,79-82 | |||
CD34+/CD38+CD38– | + | 13 | |||
+ | 83-91 | ||||
+ | + | 92,93 | |||
ROS-low | +/clinical trial | 40,94-97 | |||
NKG2D− | + | 36 |
Murine markers . | Normal vs disease . | Human markers . | Patient-derived xenograft . | Single-cell RNA sequencing . | References . |
---|---|---|---|---|---|
Lin−/LSK | 41-46 | ||||
Lin−/LSK | + | 47 | |||
LSK-SLAM | 38,48-56 | ||||
LSK-SLAM | + | 57-59 | |||
LSK-SLAM | + | 60-63 | |||
LSK-SLAM | + | + | 64-67 | ||
LSK-SLAM | CD34+/CD38+CD38− | 34,57,68-73 | |||
LSK-SLAM | + | 74,75 | |||
CD34+/CD38+CD38− | 33,76-78 | ||||
CD34+/CD38+CD38− | + | 37,39,79-82 | |||
CD34+/CD38+CD38– | + | 13 | |||
+ | 83-91 | ||||
+ | + | 92,93 | |||
ROS-low | +/clinical trial | 40,94-97 | |||
NKG2D− | + | 36 |
“Murine markers” refer to markers used to characterize stem cells in murine models. Murine studies were examined in the effect of gene knockout in both normal and disease contexts. “Human markers” refer to markers used to characterize stem cells in human cells. A ‘+’ in patient-derived xenograft column indicates if a patient-derived xenograft model was used in the given study. A ‘+’ in single-cell RNA sequencing indicates if single-cell RNA sequencing was used in the given study.